近年来，抗体药物偶联物（ADC）已成为恶性肿瘤领域的研究热点，不断在肺癌的治疗中取得突破性进展。6 月 23 日，基于 TROPION-Lung05 研究和 TROPION-Lung01 研究积极结果，美国食品药品监督管理局（FDA）加速批准 ...

Instil Bio Inc. (NASDAQ:TIL) saw its stock jump 10% after the company announced that the U.S. Food and Drug Administration ...

The majority of patients with the most common advanced or metastatic cancers in the United States do not undergo ...

CHEST guideline updates support minimally invasive resection and targeted therapy to enhance survival in Stage I–II NSCLC.

近年来，免疫治疗在非小细胞肺癌（NSCLC）围术期治疗领域取得突破性进展，围术期免疫联合化疗新辅助 + 辅助治疗已成为可手术 II - III 期 NSCLC 的新标准。在刚刚结束的 2025 ...

During June, investigators reported new data that has advanced the treatment landscape for lung cancer, including new FDA ...

Non-small cell lung cancer (NSCLC) is the most prevalent form of lung cancer, accounting for more than 80% of all lung ...

近年来，肺癌围术期免疫治疗取得了突破性进展，成为非小细胞肺癌（NSCLC）全程管理中的重要环节。在刚刚结束的 2025 年美国临床肿瘤学会（ASCO）年会上，多项围术期治疗相关研究数据重磅公布，其中基于 AEGEAN 研究的术后分子残留病灶状态与新辅助 ctDNA 动态、基因组突变及临床结局的关联数据结果以口头汇报形式重磅公布，为围术期免疫治疗获益人群的筛选提供了重要循证医学依据。

DNMT3A mutations emerged as potential biomarkers for enhanced immunotherapy benefit in non-small cell lung cancer.

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

During a live event, Neal E. Ready, MD, and participants discussed what factors justify using PD-1 plus CTLA-4 inhibitor and ...

As the leading cause of cancer-related death, lung cancer remains a noteworthy hazard to human health. NSCLC is the most ...